159 related articles for article (PubMed ID: 33283224)
21. Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
Krauss DJ; Hu C; Bahary JP; Souhami L; Gore EM; Chafe SM; Leibenhaut MH; Narayan S; Torres-Roca J; Michalski J; Zeitzer KL; Donavanik V; Sandler H; McGowan DG; Jones CU; Shipley WU
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):863-73. PubMed ID: 26104939
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Implications of a Positive Posttreatment Biopsy in Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.
Zelefsky MJ; Goldman DA; Reuter V; Kollmeier M; McBride S; Zhang Z; Varghese M; Pei X; Fuks Z
J Urol; 2019 Jun; 201(6):1127-1133. PubMed ID: 30741847
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
24. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
25. Survival predictors in patients with prostate adenocarcinoma with hormonal blockade.
Angulo JC; Redondo C; Sánchez-Chapado M; Colás B; Ropero S; López JI
Pathol Res Pract; 2016 Oct; 212(10):899-903. PubMed ID: 27502465
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of nodal relapse in definitive prostate-only irradiation.
Loi M; Incrocci L; Desideri I; Bonomo P; Detti B; Simontacchi G; Greto D; Olmetto E; Francolini G; Meattini I; Livi L
Radiol Med; 2018 Aug; 123(8):631-637. PubMed ID: 29651712
[TBL] [Abstract][Full Text] [Related]
27. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of histologic grading in patients with prostate carcinoma who are assessed by the Gleason and World Health Organization grading systems in needle biopsies obtained prior to radiotherapy.
Lilleby W; Torlakovic G; Torlakovic E; Skovlund E; Fosså SD
Cancer; 2001 Jul; 92(2):311-9. PubMed ID: 11466684
[TBL] [Abstract][Full Text] [Related]
29. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.
Zagars GK; Ayala AG; von Eschenbach AC; Pollack A
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):237-45. PubMed ID: 7836075
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of pelvic recurrence and distant metastasis in prostate carcinoma following definitive radiotherapy.
Lai PP; Perez CA; Lockett MA
Int J Radiat Oncol Biol Phys; 1992; 24(3):423-30. PubMed ID: 1399726
[TBL] [Abstract][Full Text] [Related]
31. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer.
Petrovich Z; Lieskovsky G; Langholz B; Jozsef G; Streeter OE; Skinner DG
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):600-9. PubMed ID: 12062603
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt.
Matei DV; Renne G; Pimentel M; Sandri MT; Zorzino L; Botteri E; De Cicco C; Musi G; Brescia A; Mazzoleni F; Tringali V; Detti S; de Cobelli O
Clin Genitourin Cancer; 2012 Sep; 10(3):164-73. PubMed ID: 22401754
[TBL] [Abstract][Full Text] [Related]
33. The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer.
Wang YJ; Huang CY; Hou WH; Wang CC; Lan KH; Chen CH; Yu HJ; Lai MK; Cheng AL; Liu SP; Pu YS; Cheng JC
World J Surg Oncol; 2015 Nov; 13():312. PubMed ID: 26545980
[TBL] [Abstract][Full Text] [Related]
34. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
[TBL] [Abstract][Full Text] [Related]
35. Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy.
Hirano D; Hasegawa R; Satoh K; Mochida J; Yamanaka Y; Hirakata H; Yamaguchi K; Sugimoto S; Kawata N; Takahashi S
Scand J Urol; 2014 Oct; 48(5):436-44. PubMed ID: 24730473
[TBL] [Abstract][Full Text] [Related]
36. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
37. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
38. [Prostate cancer histoseminar: Update of the 2016 WHO classification - case n
Compérat E
Ann Pathol; 2017 Jun; 37(3):228-231. PubMed ID: 28554777
[No Abstract] [Full Text] [Related]
39. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
